![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_123,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/SonomaEye-full-color-vector%5B2%5D.png)
Uveitis 3
Sunday, 3/24/2019
10:15 AM - 11:45 AM
Moderators: David S. Chu and Peter Chang
11 minutes for each presentation and discussion after each presentation
-
10: 15 am – 10:17 am: Introduction
-
10:17 am – 10:28 am: JIA and Uveitis: Current Outcomes and Outlook (Stephen Anesi, MD)
-
10:28 am – 10:39 am: Biologics for JIA-Associated Uveitis (Nisha Acharya, MD)
-
10:39 am – 10:50 am: Long Term Outcome of Adalimumab Treatment in Non-Infectious Uveitis: VISUAL III Trial Update (David S. Chu, MD)
-
10:50 am – 11:01 am: Retinal Vasculitis in Teenagers (Shwu-Jiuan Sheu, MD)
-
11:01 am – 11:12 am: PPV/EL/Cryo in Management of Pars Planitis (Peter Chang, MD)
-
11:12 am - 11:23 am: Intraocular Lens Management in Pediatric Uveitis (Sarju S. Patel, MD)
-
11:23 am – 11:34 am: ERG Utilization in Uveitis (Will Ayliffe, FRCS, PhD)
-
11:34 am – 11:45 am: Testing a JAK Inhibitor’s Safety and Efficacy in Adults with Noninfectious Uveitis (Timothy Watkins, MD, MSc)